[1]李小丹① 郭红燕 李圆**.初级与次级预防性使用聚乙二醇化重组人粒细胞集落刺激因子在卵巢癌初始肿瘤细胞减灭术后化疗的价值[J].中国微创外科杂志,2022,01(3):197-201.
　Li Xiaodan,Guo Hongyan*,Li Yuan*..On Value of Primary and Secondary Prophylactic Use of Pegylated Recombinant Human Granulocyte Colonystimulating Factor in Chemotherapy After Primary Tumor Cell Reduction for Ovarian Cancer[J].Chinese Journal of Minimally Invasive Surgery,2022,01(3):197-201.
点击复制

初级与次级预防性使用聚乙二醇化重组人粒细胞集落刺激因子在卵巢癌初始肿瘤细胞减灭术后化疗的价值()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2022年3期
页码:
197-201
栏目:
临床研究
出版日期:
2022-06-02

文章信息/Info

Title:
On Value of Primary and Secondary Prophylactic Use of Pegylated Recombinant Human Granulocyte Colonystimulating Factor in Chemotherapy After Primary Tumor Cell Reduction for Ovarian Cancer
作者:
李小丹① 郭红燕 李圆**
(北京大学第三医院妇产科,北京100191)
Author(s):
Li Xiaodan;  Guo Hongyan*;  Li Yuan*.
*Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 100191, China
关键词:
聚乙二醇化重组人粒细胞集落刺激因子; 卵巢癌; 化疗; 中性粒细胞减少
Keywords:
Pegylated recombinant human granulocyte colony stimulating factor; Ovarian cancer; Chemotherapy; Neutropenia
文献标志码:
A
摘要:
目的探讨初级与次级预防性使用聚乙二醇化重组人粒细胞集落刺激因子(pegylated recombinant human granulocyte colonystimulating factor，PEGrhGCSF)在卵巢癌初始肿瘤细胞减灭术后化疗的价值。方法2019年1月~2020 年6月我院76例卵巢癌初始肿瘤细胞减灭术后行紫杉醇和卡铂联合化疗，根据初次预防性使用PEGrhGCSF分为初级预防组(n=49)和次级预防组(n=27)，比较2组中性粒细胞减少发生率、需要补充重组人粒细胞集落刺激因子（recombinant human granulocyte colonystimulating factor，rhGCSF）率、中性粒细胞减少相关重复住院率、中性粒细胞减少相关化疗周期延迟发生率等。结果第一、二疗程中，初级预防组3、4度中性粒细胞减少发生率分别为8.2%（4/49）、6.1%（3/49），明显低于次级预防组发生率66.7%（18/27）、37.0%（10/27）(Z=-6.569,P=0.000;Z=-4.338，P=0.000)。在第三~六疗程中，2组中性粒细胞减少发生率无明显统计学差异(Z=-0938,P=0.348;Z=-0.145,P=0.884;Z=-1.069,P=0.285;Z=-0.027，P=0.978)。化疗结束后初级预防组9例因中性粒细胞减少需补充rhGCSF，发生率18.4%(9/49)，次级预防组22例，发生率81.5%(22/27)，2组比较差异有统计学意义(χ2=28.711，P=0.000)。初级预防组2例因中性粒细胞减少需重复住院，发生率4.1%(2/49)，次级预防组7例，发生率25.9%(7/27)，2组比较差异有统计学意义(χ2=6002，P=0.014)。初级预防组1例因中性粒细胞减少导致化疗延迟，发生率2.0%(1/49)，次级预防组5例，发生率18.5%(5/27)，2组比较差异有统计学意义(χ2=4.431，P=0.035)。结论卵巢癌初始肿瘤细胞减灭术后化疗过程中初级预防性应用PEGrhGCSF可显著降低第一、二疗程中性粒细胞减少发生率，从而降低中性粒细胞减少相关重复住院率，保证化疗周期如期顺利进行。
Abstract:
ObjectiveTo investigate the value of primary and secondary prophylactic use of pegylated recombinant human granulocyte colonystimulating factor(PEGrhGCSF) in chemotherapy after primary tumor cell reduction for ovarian cancer.MethodsA retrospective analysis was made on 76 patients with ovarian cancer receiving chemotherapy in our hospital from January 2019 to June 2020. After initial tumor cell reduction, they were divided into primary prevention group (n=49) and secondary prevention group (n=27) according to the first use of PEGrhGCSF. The rate of different degrees of neutropenia, need to add recombinant human granulocyte colonystimulating factor(rhGCSF), neutropeniarelated repeated hospitalization, and the number of cases of delayed neutropeniarelated chemotherapy cycle were compared between the two groups.ResultsIn the first and second courses of chemotherapy, there were 4 cases and 3 cases of grade 3 and 4 neutropenia in the primary prevention group, and the incidence rate was 8.2%(4/49) and 6.1%(3/49), which were significantly lower than those in the secondary prevention group ［667%(18/27) ,Z=-6.569,P=0.000;37.0%(10/27),Z=-4.338, P=0000］. In the third to sixth courses, there were no significant differences in the incidence of different degrees of neutropenia between the two groups (Z=-0938,P=0.348;Z=-0.145,P=0.884;Z=-1.069,P=0.285;Z=-0.027，P=0.978). In the primary prevention group, 9 patients were required to add recombinant human granulocyte colony stimulating factor after neutropenia, with an incidence of 18.4%(9/49), and in the secondary prevention group, 22 patients were required to add recombinant human granulocyte colony stimulating factor (81.5%), with a statistically significant difference between the two groups (χ2=28.711, P=0.000). There were 2 cases (4.1%) in the primary prevention group and 7 cases (25.9%) in the secondary prevention group, and the difference was statistically significant (χ2=6.002, P=0.014). Delayed chemotherapy due to neutropenia was found in 1 case (2.0%) in the primary prevention group and 5 cases (185%) in the secondary prevention group, the difference between the two groups being statistically significant (χ2=4431, P=0035).ConclusionPrimary prophylactic use of PEGrhGCSF during chemotherapy after initial reduction of ovarian cancer cells can significantly reduce the incidence of neutropenia in the first and second courses of chemotherapy, thus reducing the rate of repeated neutropenia related hospitalizations and ensuring the smooth chemotherapy cycle as scheduled.

参考文献/References:

[1]Stewart C, Ralvea C, Lock wood S. Ovarian cancer: An integrated review. Semin Oncol Nurs,2019,35(2):151-156.
[2]侯征,牛子儒,郭红燕，等.晚期上皮性卵巢癌腹腔镜和开腹初次肿瘤细胞减灭术对比分析.中国微创外科杂志,2021,21(3):199-204.
[3]沈源明，谢幸.上皮性卵巢癌一线化疗.实用妇产科杂志,2020,36(2):81-83.
[4]中国医师协会微无创医学专业委员会妇科肿瘤专业委员会(学组)，中国优生科学协会生殖道疾病诊治分会，中国优生科学协会肿瘤生殖学分会.低级别浆液性卵巢癌的专家共识(2020 年版).中国癌症防治杂志,2020,12(2):117-123.
[5]中国抗癌协会肿瘤临床化疗专业委员会，中国抗癌协会肿瘤支持治疗专业委员会.肿瘤化疗导致的中性粒细胞减少诊治专家共识(2019年版).中国医学前沿杂志(电子版),2019, 11(12):86-92.
[6]Fernandes R, Mazzarello S, Stober C, et al. Primary febrile neutropenia prophylaxis for patients who receive FECD chemotherapy for breast cancer: a systematic review. J Glob Oncol,2018,4(9):1-8.
[7]蔡智慧，李卉，东丽，等.聚乙二醇化重组人粒细胞集落刺激因子预防恶性肿瘤化疗Ⅳ度骨髓抑制27例.安徽医药,2019,23(11):2287-2290.
[8]Lee YJ， Lee IH, Kim YJ, et al. Enaluation of various kinetic parameters of CA125 in patients with advancedstage ovarian cancer undergoing neoadjuvant chemotherapy. PLoS One,2018,13(9):e0203366.
[9]胡雪莲,赵勇.中性粒细胞发育分化调控机制.中华微生物学和免疫学杂志,2013,33(5):385-392.
[10]杨晟, 何小慧,刘鹏,等.聚乙二醇和重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少的有效性分析.中国肿瘤临床,2015,42(12):626-631.
[11]申锋，周宇红，何健.等.聚乙二醇化重组人粒细胞刺激因子在软组织肉瘤患者化疗后使用的临床分析.肿瘤,2020,40(5):355-360.
[12]杨艳迪, 陆滢, 叶佩佩.PEGrhGCSF预防弥漫大B细胞淋巴瘤患者化疗后中性粒细胞缺乏的效果观察.浙江医学,2020,42(6):587-593.
[13]Klastersky J, Awada A. Prevention of febrile neutropenia in chemotherapytreated cancer patients: pegylated versus standard myeloid colony stimulating factors. Do we have a choice? Crit Rev Oncol Hematol,2011,78(1):17-23.
[14]Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of longacting granulocyte colonystimulating factors for prophylaxis of chemotherapyinduced neutropenia in patients with cancer: a systematic review. Support Care Cancer,2015,23(2):525-545.
[15]Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropenia: ESMO clinical practiceguidelines. Ann Oncol,2016,27(Suppl 5):v111-v118.

备注/Memo

备注/Memo:
基金项目：北京大学第三医院临床重点人才项目（BYSYZD2019031）**通讯作者，Email:yuanli@bjmu.edu.cn ①(广东省中医院珠海医院妇科，珠海519000)
更新日期/Last Update: 2022-06-02